Disease Biomarkers in the Precision Medicine Era: A Comprehensive Multi-omics Analysis

Dear Colleagues,

Late-stage diagnosis often leads to advanced tumors, resulting in unfavorable survival outcomes despite continuous research and advancements in treatment modalities. Precision medicine efforts in disease have been prominent due to a comprehensive understanding of the impact of genetic mutations on disease initiation and progression. The recent surge in precision medicine techniques represents a groundbreaking era, where advancements in measurement technologies enable the sequencing of thousands of exomes, whole genomes, and the exploration of entire genomes, transcriptomes, proteomes, and metabolites at the single-cell level. Precision medicine, currently undergoing a multi-omics revolution, leverages insights from both germline and somatic cell differences to tailor treatments for individual disease patients. Molecular characterization, enabled by the diverse assessment of multi-omics, offers clinicians valuable information for personalized treatment planning.

This Special Issue aims to achieve precision in disease medicine through a multi-omics approach, emphasizing the fundamental understanding of disease biology. We welcome submissions that utilize multi-omics methodologies to uncover novel findings or identify new targets in disease research. The focus is on effectively generating, analyzing, and interpreting multi-omics data to inform decisions based on precision medicine. Authors are encouraged to submit research and review papers covering various aspects of the field, such as the basic understanding of genomics and signaling pathways, diagnostic and prognostic biomarkers, pharmacogenomic biomarkers, molecular diagnosis through gene expression profiling, molecular targets driving disease progression, drug development against these targets, clinical trials of new drugs, and investigations into disease epigenetics.

Dr. Chia-Jung Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• personalized medicine
• disease biomarkers: screening and diagnosis
• multi-omics analysis
• epidemiology